MX2020009074A - Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar. - Google Patents
Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar.Info
- Publication number
- MX2020009074A MX2020009074A MX2020009074A MX2020009074A MX2020009074A MX 2020009074 A MX2020009074 A MX 2020009074A MX 2020009074 A MX2020009074 A MX 2020009074A MX 2020009074 A MX2020009074 A MX 2020009074A MX 2020009074 A MX2020009074 A MX 2020009074A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- bile duct
- associated conditions
- methods
- oligonucleotides
- Prior art date
Links
- 210000000013 bile duct Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102100028914 Catenin beta-1 Human genes 0.000 abstract 3
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
- 210000003494 hepatocyte Anatomy 0.000 abstract 2
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637973P | 2018-03-02 | 2018-03-02 | |
| PCT/US2019/018184 WO2019168686A1 (en) | 2018-03-02 | 2019-02-15 | Methods and compositions for treating bile duct paucity-associated conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009074A true MX2020009074A (es) | 2020-10-08 |
Family
ID=67805109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009074A MX2020009074A (es) | 2018-03-02 | 2019-02-15 | Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11634715B2 (https=) |
| EP (1) | EP3740248A4 (https=) |
| JP (1) | JP2021517909A (https=) |
| KR (1) | KR20200127008A (https=) |
| CN (1) | CN112055597A (https=) |
| AU (1) | AU2019228448A1 (https=) |
| CA (1) | CA3092089A1 (https=) |
| IL (1) | IL277015A (https=) |
| MX (1) | MX2020009074A (https=) |
| WO (1) | WO2019168686A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3092089A1 (en) | 2018-03-02 | 2019-09-06 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for treating bile duct paucity-associated conditions |
| WO2024262593A1 (ja) * | 2023-06-22 | 2024-12-26 | 公益財団法人川崎市産業振興財団 | 核酸の血中安定性を向上させ、標的化効率を向上させる方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3037538T3 (da) | 2010-07-06 | 2019-06-24 | Dicerna Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna |
| US9468670B2 (en) * | 2011-04-01 | 2016-10-18 | Texas A&M University System | Melatonin-based treatment and diagnosis of bile duct disease |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| AU2015330670B2 (en) * | 2014-10-10 | 2022-01-06 | Novo Nordisk Health Care Ag | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| CA3092089A1 (en) | 2018-03-02 | 2019-09-06 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for treating bile duct paucity-associated conditions |
-
2019
- 2019-02-15 CA CA3092089A patent/CA3092089A1/en active Pending
- 2019-02-15 US US16/975,946 patent/US11634715B2/en active Active
- 2019-02-15 AU AU2019228448A patent/AU2019228448A1/en not_active Abandoned
- 2019-02-15 WO PCT/US2019/018184 patent/WO2019168686A1/en not_active Ceased
- 2019-02-15 JP JP2020568662A patent/JP2021517909A/ja active Pending
- 2019-02-15 MX MX2020009074A patent/MX2020009074A/es unknown
- 2019-02-15 KR KR1020207027733A patent/KR20200127008A/ko not_active Ceased
- 2019-02-15 CN CN201980029432.6A patent/CN112055597A/zh active Pending
- 2019-02-15 EP EP19761345.8A patent/EP3740248A4/en not_active Withdrawn
-
2020
- 2020-08-31 IL IL277015A patent/IL277015A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3740248A1 (en) | 2020-11-25 |
| KR20200127008A (ko) | 2020-11-09 |
| EP3740248A4 (en) | 2022-01-26 |
| JP2021517909A (ja) | 2021-07-29 |
| US11634715B2 (en) | 2023-04-25 |
| CA3092089A1 (en) | 2019-09-06 |
| WO2019168686A1 (en) | 2019-09-06 |
| CN112055597A (zh) | 2020-12-08 |
| US20210010005A1 (en) | 2021-01-14 |
| IL277015A (en) | 2020-10-29 |
| AU2019228448A1 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011006A (es) | Pcsk9 dirigido a oligonucleótidos para el tratamiento de la hipercolesterolemia y afecciones relacionadas. | |
| MX2020000154A (es) | Composiciones y métodos para inhibir la expresión de hmgb1. | |
| MX2020007582A (es) | Composiciones y metodos para inhibir la expresion de aldehido deshidrogenasa mitocondrial 2 (aldh2). | |
| PH12019500245A1 (en) | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | |
| ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
| MX2021007855A (es) | Composiciones y metodos para inhibir la expresion de hmgb1. | |
| TN2020000038A1 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| ZA201902226B (en) | Aav treatment of huntington's disease | |
| EP4177346A3 (en) | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases | |
| MX2015011943A (es) | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. | |
| FI3604532T3 (fi) | Uusia crispr-entsyymejä ja järjestelmiä | |
| WO2009006577A3 (en) | Compositions and methods for inhibiting ezh2 | |
| MX2023003672A (es) | Composiciones y metodos para inhibir la expresion del gen de alfa-1 antitripsina. | |
| HK1252852A1 (zh) | 阻止HIF2α基因表达的组合物及方法 | |
| WO2012006181A3 (en) | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer | |
| MX2020009072A (es) | Composiciones y metodos para inhibir la expresion de gys2. | |
| WO2012142313A3 (en) | Micro-rna inhibitors and their uses in disease | |
| WO2008092099A3 (en) | Compositions and methods for treating hematopoietic malignancies | |
| MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
| WO2017197141A3 (en) | Targeted treatment of androgenic alopecia | |
| MX2020009074A (es) | Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar. | |
| MX2021009754A (es) | Metodos y composiciones para inhibir la expresion de cyp27a1. | |
| PH12019500737A1 (en) | Improvements in or relating to gene silencing | |
| JO3769B1 (ar) | علاج RNAi لعدوى فيروس التهاب الكبد B | |
| HK1241287A1 (en) | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |